Concept Framework of Vaccines-Like Administration to Preatherosclerosis
Yue Zheng,Tong Li
DOI: https://doi.org/10.1161/circresaha.118.314633
IF: 23.213
2019-01-01
Circulation Research
Abstract:HomeCirculation ResearchVol. 124, No. 4Concept Framework of Vaccines-Like Administration to Preatherosclerosis Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBConcept Framework of Vaccines-Like Administration to Preatherosclerosis Yue Zheng and Tong Li Yue ZhengYue Zheng From the Department of Cardiology, Third Central Clinical College of Tianjin Medical University, China (Y.Z.) Department of Cardiology, Tianjin Key Laboratory of Artificial Cell (Y.Z., T.L.) Department of Cardiology, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin, China (Y.Z., T.L.) Department of Cardiology, Tianjin Institute of Hepatobiliary Disease, China (Y.Z., T.L.). Search for more papers by this author and Tong LiTong Li Correspondence to Tong Li, PhD, Department of Heart Centre, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Qixiangtai Rd 22, Heping District, Tianjin 300170, China. Email E-mail Address: [email protected] Department of Cardiology, Third Central Hospital of Tianjin, China (T.L.) Department of Cardiology, Tianjin Key Laboratory of Artificial Cell (Y.Z., T.L.) Department of Cardiology, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin, China (Y.Z., T.L.) Department of Cardiology, Tianjin Institute of Hepatobiliary Disease, China (Y.Z., T.L.). Search for more papers by this author Originally published14 Feb 2019https://doi.org/10.1161/CIRCRESAHA.118.314633Circulation Research. 2019;124:488–490is corrected byCorrection to: Concept Framework of Vaccines-Like Administration to PreatherosclerosisOther version(s) of this articleYou are viewing the most recent version of this article. Previous versions: February 14, 2019: Previous Version of Record Coronary artery disease (CAD) is the most common cause of death worldwide, responsible for ≈1 in every 7 deaths, with the majority occurring in low-income and middle-income countries, and atherosclerosis has emerged as the leading cause of morbidity and mortality in patients worldwide with some chronic diseases such as diabetic and CAD. For instance, conservatively estimated, nowadays 290 million people develop heart diseases in China, which mostly are CAD and hypertension. Despite high-intensity statin treatment and other standard-of-care measures, even in those receiving inhibitors of PCSK9 (proprotein convertase subtilisin/kexin type 9) or ezetimibe on top of statins, we still face an unacceptable burden of recurrent cardiovascular events. At any rate, this issue is urgent and cannot be ignored.Macrophage lipid uptake may be viewed as a protective response that backfires. Ingesting oxidized lipoproteins, like ingesting microbes, involves the scavenging of substances perceived to be dangerous. Lipoprotein recognition and consequent ingestion morphs macrophages into foam cells, many of which eventually die and contribute to a large lipid core, a characteristic of lesions most vulnerable to rupture.1Current Therapeutic Situation of CADThe extent and severity of clinically significant coronary artery stenosis have been correlated with long-term mortality, and, as such, coronary angiography has an important role in risk stratification. The presence of clinically significant ischemia, determined in various ways, is widely thought to be potentially useful in identifying patients who would benefit prognostically from revascularization, but this approach remains controversial, particularly in patients with mild or absent symptoms.Medical therapy with proven prognostically active agents is now the core therapy for stable CAD, especially for early atherosclerosis. In general, because of this complexity, it is not practical to communicate the detailed evidence with all its intrinsic risk-benefits trade-offs to patients and ask them to decide, recognizing that even expert clinicians fully familiar with the evidence often cannot agree on a best course.So further researches are still needed, and it may be better to pay more attention to studies on physiology and pathophysiology of coronary arteries, especially in the period of pre-atherosclerosis not illness.LipophagyMononuclear phagocytes contribute to all stages of CAD, illustrating the link between inflammation and atherosclerosis2 (Figure). Besides, macrophage foam cell formation, a hallmark of the nascent atheroma, is a typical pathological change associated with early atherosclerosis. It is characterized by an imbalance of cholesterol influx and efflux, and the accumulation of cholesterol esters within cytoplasmic lipid droplets. In disease, autophagy has been seen as an adaptive response to stress, which promotes survival, whereas in other cases it appears to promote cell death and morbidity.2Download figureDownload PowerPointFigure. Roles of myeloid cells in the evolution of the atherosclerotic plaque. This figure depicts the participation of myeloid cells in the evolution of the atheroma from the inception (left) through the progression and complication of the plaque (middle to right). Dendritic cells may populate the normal arterial intima. Early in the atherogenesis, monocytes adhere to endothelial cells (left). The adherent monocytes can diapedese into the intima and mature into macrophages. These cells imbibe lipid and become foam cells, a hallmark of the atheromatous plaque. These cells populate the lipid core of the evolving atheroma (yellow central potion, middle). These foamy macrophages can elaborate many mediators that amplify and sustain the atherogenic process. In particular, they can secrete interstitial collagenases, members of the MMP family, that can degrade the collagen fibrils that lend strength to the fibrous cap that overlies the lipid core of the established atheroma. Cleavage of collagen in the plaque’s fibrous cap allows contact of the blood coagulation components with the procoagulant tissue factor produced by the plaque macrophages. Thus, disruption of the plaque by a fracture of the fibrous cap triggers thrombosis that leads to the most dreaded clinical complications of atherosclerosis, such as the acute coronary syndromes and many ischemic strokes. Macrophages can die within plaques, as shown by the cell with the pyknotic nucleus casting off apoptotic bodies that can bear tissue factor. Macrophages can also release microparticles that can provide a nidus for spotty calcification associated with plaque instability. Calcium mineral can coalesce into plates that complicate the advanced atherosclerotic plaque. As plaques mature, they can become less cellular and accumulate more extracellular matrix. In regions of plaques rich in proteoglycan and glycosaminoglycans, endothelial cells can detach, exposing blood to underlying collagen and other thrombogenic mediators that can instigate clot formation. This process, denoted superficial erosion, can lead to recruitment of polymorphonuclear leukocytes. Dying granulocytes release DNA that can associate with the pro-oxidant enzyme myeloperoxidase, the procoagulant tissue factor, and other enzymes associated with further endothelial damage and thrombosis. These NETs can further entrap platelets, promoting propagation of thrombi. The dendritic cells in plaques can present antigen to T cells, providing a link between innate and adaptive immunity. Mast cells in the adventitia of arteries can elaborate numerous mediators, including histamine, heparin, serine proteinases, and cytokines, that can amplify atherogenesis and lesion complication. Thus, myeloid cells participate in all phases of atherogenesis, from lesion initiation (left) through thrombotic complications (middle and right). Reprinted from Swirski et al5 with permission. Copyright ©2016, American Society for Microbiology.Because autophagy decreases with age and age is a major risk factor for CAD, the role of autophagy in the development of this disease is suggested. Proteins involved in autophagy are reduced with age in both human and mouse coronary artery. Autophagy is constantly activated in normal macrophage, but it is compromised with age and precedes macrophage foam cell formation.3 In addition, abnormal lipids metabolism is also one of the most significant risk factors of atherosclerosis.Macrophages in atherosclerotic lesions actively participate in lipoprotein ingestion and accumulation giving rise to foam cells filled with lipid droplets. Accumulation of foam cells contributes to lipid storage and atherosclerotic plaque growth. Macrophages populating the atherosclerotic plaque have a decreased ability to migrate, which leads to failure of inflammation resolution and to further progression of the lesion into complicated atherosclerotic plaque.4Lipophagy, a selective form of macroautophagy, has been proposed recently. Accordingly, cytosolic lipid droplets are sequestered by double-membrane vacuoles called autophagosomes and subsequently delivered to the lysosome for degradation by lysosomal acid lipase. This pathway is activated in lipid-loaded macrophages and contributes considerably to cholesterol efflux and cholesterol esters hydrolysis in cytosolic lipid droplets while preventing cellular lipid accumulation and foam cell formation.However, more and more researches have focused on the relationship between autophagy and foam cell formation. Maybe it is not the best target.Hypothetically, macrophages can prevent atherosclerosis by scavenging and removing surplus lipoproteins from the artery wall, without becoming foam cells and without escalating inflammation. However, macrophage is transferred to foam cell in a way partly hidden from our view.5 What we should do is knowing more details about the difference between macrophage and foam cell, for instance, surface markers and the change of expression level. Although large amounts of proteins in foam cells had been found, no suitable protein is screened until now. The first thing we should do is to screen the highly sensitive and specific proteins in macrophage foam cells as a target for treatment.If we find such proteins, the ability to migrate of macrophages populating the atherosclerotic plaque can be increased to prevent foam cell formation. Besides, the therapeutic effect will become better if this mechanism has a synergistic effect with lipophagy in early atherosclerosis. In other words, what we should care most is to screen the molecules, biomarkers, or mechanisms that can make macrophages skip the phase of foam cell formation to inflammation resolution.Vaccines-Like Therapeutic AdministrationVaccines have historically been the most effective means to fight and eradicate infectious diseases. Limitations to their effectiveness, nevertheless, exist. Sometimes, protection fails because the host’s immune system simply does not respond adequately or at all. Lack of response commonly results from clinical factors such as diabetes mellitus, steroid use, HIV infection, or age. It also might fail for genetic reasons if the host’s immune system includes no strains of B cells that can generate antibodies suited to reacting effectively and binding to the antigens associated with the pathogen. Generally speaking, vaccines can be prophylactic (eg, to prevent or ameliorate the effects of a future infection by a natural or wild pathogen), or therapeutic (eg, vaccines against cancer are being investigated).Hence, taking advantage of the operation mode of vaccines administration (regular injection and therefore checking the titer) may be the best resolution to those limitations. Similar to administration mode of hepatitis B vaccines, this easy way can be applied to prevent some chronic diseases, for instance, early atherosclerosis and hypertension. If the problems of headstream have been partly solved, the morbidity and mortality of subsequent adverse events, such as acute myocardial infarction will be decreased a lot. At that time, maybe atherosclerosis will be resolved by human being. So, vaccines-like administration for early atherosclerosis may be worth a shot.DisclosuresNone.Sources of FundingThis study was financially supported by key supporting project of Tianjin Science and Technology Commission (16YFZCSY01060); key fund of Tianjin Municipal Commission of Health and Family Planning (2014KR01); key project of Tianjin Health Industry (14KG112); and Youth Fund of Tianjin Science and Technology Commission (17JCQNJC10000).FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Tong Li, PhD, Department of Heart Centre, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Qixiangtai Rd 22, Heping District, Tianjin 300170, China. Email [email protected]comReferences1. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure.Science. 2013; 339:161–166. doi: 10.1126/science.1230719CrossrefMedlineGoogle Scholar2. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates.Clin Sci (Lond). 2018; 132:1243–1252. doi: 10.1042/CS20180306CrossrefMedlineGoogle Scholar3. Razani B, Feng C, Coleman T, Emanuel R, Wen H, Hwang S, Ting JP, Virgin HW, Kastan MB, Semenkovich CF. Autophagy links inflammasomes to atherosclerotic progression.Cell Metab. 2012; 15:534–544. doi: 10.1016/j.cmet.2012.02.011CrossrefMedlineGoogle Scholar4. Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis.Circ Res. 2014; 114:1757–1771. doi: 10.1161/CIRCRESAHA.114.301174LinkGoogle Scholar5. Swirski FK, Nahrendorf M, Libby P. Mechanisms of myeloid cell modulation of atherosclerosis.Microbiol Spectr. 2016; 4:MCHD-0026-2015.CrossrefGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesCorrection to: Concept Framework of Vaccines-Like Administration to PreatherosclerosisCirculation Research. 2019;124:e62-e62 February 15, 2019Vol 124, Issue 4 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.118.314633PMID: 30763210 Originally publishedFebruary 14, 2019 Keywordsinflammationcholesterol estersautophagosomesfoam cellslipid dropletsPDF download Advertisement